핵의학 영상 진단 장비 시장 - 세계 예측(2026-2032년)

The Nuclear Imaging Equipment Market is projected to grow by USD 9.55 billion at a CAGR of 6.14% by 2032.

Executive Summary: Nuclear Imaging Equipment in Precision Diagnostics

Nuclear imaging equipment is a core pillar of precision diagnostics, enabling clinicians to visualize physiological processes rather than anatomy alone. Modalities such as single-photon emission computed tomography (SPECT), positron emission tomography (PET), hybrid PET/CT, SPECT/CT, and PET/MRI support high-value applications across oncology, cardiology, neurology, endocrinology, infection imaging, and theranostics. Demand is being shaped by the rising clinical burden of cancer, cardiovascular disease, and neurodegenerative disorders, alongside wider adoption of radiotracers that improve disease detection, staging, therapy selection, and treatment monitoring. The sector is also influenced by hospital modernization programs, expanding radiopharmacy networks, regulatory requirements for radiation safety, and the growing role of molecular imaging in personalized medicine. As healthcare systems prioritize earlier diagnosis and evidence-based care pathways, nuclear imaging equipment is increasingly evaluated not only for image quality, but also for workflow efficiency, dose optimization, uptime, interoperability, and lifecycle cost performance.

Transformative Shifts in the Nuclear Imaging Equipment Landscape

The nuclear imaging equipment landscape is undergoing a structural shift from stand-alone diagnostic systems toward integrated, software-enabled molecular imaging platforms. Hybrid imaging has become central to clinical decision-making because it combines metabolic or functional data with anatomical localization, improving diagnostic confidence in complex disease pathways. Equipment design is evolving around digital detectors, time-of-flight PET capabilities, advanced reconstruction algorithms, motion correction, automated quality control, and lower-dose imaging protocols. At the same time, care delivery is shifting from tertiary academic centers toward broader hospital networks and specialized imaging centers, creating demand for scalable systems that balance performance with operational simplicity. The expansion of theranostics is another transformative force, as imaging equipment is increasingly linked with targeted radiopharmaceutical therapy planning, dosimetry, and response assessment. Supply chain resilience, isotope availability, trained workforce capacity, reimbursement policy, and compliance with radiation protection standards remain critical determinants of adoption across both advanced and emerging healthcare systems.

Cumulative Impact of Artificial Intelligence on Nuclear Imaging

Artificial intelligence is becoming a cumulative enabler across the nuclear imaging equipment value chain, from acquisition and reconstruction to interpretation, workflow orchestration, and quality assurance. AI-supported reconstruction can help improve image quality, reduce noise, and enable shorter acquisition times or lower administered activity when validated under clinical protocols. Automated segmentation, lesion detection support, quantification tools, and standardized uptake analytics are strengthening consistency in oncology, cardiology, and neurology workflows. AI also supports operational performance by assisting with patient scheduling, scanner utilization, protocol selection, motion detection, and predictive maintenance. However, implementation depends on transparent validation, regulatory clearance, cybersecurity safeguards, clinical oversight, and integration with radiology information systems, picture archiving systems, electronic health records, and radiopharmacy data streams. The strongest impact is expected where AI complements nuclear medicine specialists by reducing repetitive tasks, improving reproducibility, and supporting measurable clinical productivity without compromising safety or diagnostic accountability.

Key Regional Insights Across Nuclear Imaging Equipment Adoption

Asia-Pacific is advancing rapidly as healthcare infrastructure investment, expanding cancer care capacity, and rising adoption of PET/CT and SPECT/CT increase access to molecular imaging, with China, India, Japan, South Korea, and Australia serving as important demand centers. North America maintains a highly developed nuclear imaging ecosystem supported by established reimbursement pathways, clinical guideline integration, radiopharmaceutical availability, and strong use of PET in oncology, cardiac imaging, and neurological assessment. Latin America is improving access through public and private hospital investment, although uneven equipment distribution, isotope logistics, reimbursement variability, and specialist availability influence utilization across countries. Europe benefits from mature nuclear medicine networks, regulatory harmonization, clinical research collaboration, and strong use of hybrid imaging, while equipment procurement is shaped by quality standards, radiation protection rules, and modernization of aging diagnostic infrastructure. The Middle East is expanding advanced imaging capacity through tertiary care development, national cancer programs, and medical city projects, particularly where oncology, cardiology, and specialty care programs are being prioritized. Africa shows selective but important progress, with nuclear imaging concentrated in major urban and academic centers; broader adoption depends on workforce development, cyclotron or generator access, service support, stable radiotracer supply, and sustainable funding models.

Key Group Insights Shaping Nuclear Imaging Equipment Demand

ASEAN countries are strengthening nuclear imaging capabilities through hospital upgrades, oncology service expansion, and cross-border healthcare investment, though adoption varies by income level, specialist availability, reimbursement readiness, and radiotracer supply infrastructure. GCC countries are emphasizing advanced diagnostic imaging as part of broader healthcare transformation programs, with investments in tertiary hospitals, cancer centers, and high-acuity care pathways supporting PET/CT and SPECT/CT deployment. The European Union benefits from coordinated regulatory frameworks, cross-country research collaboration, and well-established nuclear medicine standards, creating a favorable environment for quality assurance, radiation safety, and clinical integration. BRICS countries represent a diverse adoption landscape: China and India are expanding capacity through healthcare modernization and oncology demand, Brazil and South Africa continue to build access through leading urban centers, and Russia maintains established nuclear medicine capabilities shaped by domestic healthcare priorities. G7 countries generally demonstrate mature equipment bases, advanced radiopharmaceutical use, established reimbursement processes, and strong integration of nuclear imaging into oncology, cardiology, and neurology pathways. NATO member states overlap significantly with advanced European and North American healthcare systems, where equipment resilience, secure supply chains, cybersecurity, and high-reliability hospital infrastructure are increasingly relevant to diagnostic continuity.

Key Country Insights for Nuclear Imaging Equipment Markets

The United States remains one of the most developed environments for nuclear imaging equipment, supported by extensive PET and SPECT utilization in oncology, cardiology, and neurology, as well as mature radiopharmacy, accreditation, and clinical infrastructure. Canada emphasizes quality-controlled imaging services within publicly funded healthcare settings, with procurement shaped by provincial planning, access equity, and equipment renewal needs. Mexico is expanding advanced imaging access in major metropolitan and private healthcare centers, while wider availability is influenced by reimbursement, trained personnel, and radiotracer distribution. Brazil has the largest healthcare system in Latin America and uses nuclear imaging across major hospital networks, although geographic disparities affect access beyond leading urban centers. The United Kingdom supports nuclear imaging through guideline-driven cancer, cardiac, and neurological care pathways, with attention to capacity, workforce, and equipment modernization. Germany benefits from a strong clinical and technical base for hybrid imaging, radiopharmaceutical use, and hospital-based nuclear medicine. France maintains established nuclear medicine services with emphasis on regulated radioprotection, oncology imaging, and specialist care delivery. Russia has long-standing nuclear medicine capabilities and continues to apply SPECT and PET across oncology and cardiology services, supported by national healthcare infrastructure priorities. Italy and Spain both show mature use of nuclear imaging in public and private hospital networks, with modernization focused on hybrid systems, efficient patient throughput, and compliance with radiation safety requirements. China is rapidly expanding molecular imaging capacity through hospital construction, oncology demand, domestic healthcare modernization, and wider clinical adoption of hybrid imaging. India is increasing access to PET/CT and SPECT/CT through cancer center development and private-sector diagnostic investment, while affordability, isotope logistics, and workforce training remain important. Japan has advanced imaging infrastructure and strong clinical adoption in oncology, neurology, and cardiology, supported by sophisticated hospital networks and aging-population health needs. Australia maintains high-quality nuclear medicine services across major cities, with access shaped by geography, specialist distribution, and public-private service models. South Korea demonstrates strong uptake of advanced diagnostic technologies, supported by high hospital digitization, oncology care demand, established nuclear medicine expertise, and robust tertiary care infrastructure.

Actionable Recommendations for Nuclear Imaging Equipment Leaders

Industry leaders should prioritize equipment strategies that align clinical performance with operational efficiency, including faster scan protocols, dose optimization, automated quality control, and high system uptime. Product portfolios should support hybrid imaging, theranostic workflows, quantitative analytics, and seamless integration with hospital IT systems. Commercial teams should adapt offerings to regional realities, including financing flexibility, service coverage, radiotracer access, training programs, and total cost of ownership requirements. Partnerships with hospitals, radiopharmacies, academic centers, and regulatory stakeholders can strengthen adoption by addressing workflow redesign, staff education, and compliance readiness. Leaders should also invest in AI validation, cybersecurity, interoperability, and lifecycle support, as buyers increasingly evaluate digital capability alongside hardware performance. In emerging markets, sustainable growth depends on workforce development, service reliability, practical deployment models, and support structures that can function in environments with uneven infrastructure.

Research Methodology for Nuclear Imaging Equipment Analysis

A rigorous research methodology for nuclear imaging equipment analysis should combine secondary and primary evidence from validated healthcare, regulatory, clinical, and industry sources. Secondary research should examine peer-reviewed nuclear medicine literature, clinical guidelines, hospital procurement trends, regulatory documentation, reimbursement policies, radiopharmaceutical supply considerations, radiation safety standards, and public health data on cancer, cardiovascular disease, and neurological disorders. Primary research should include structured interviews with nuclear medicine physicians, radiologists, cardiologists, oncologists, hospital administrators, radiopharmacists, medical physicists, procurement leaders, and service engineers. Findings should be triangulated across clinical adoption indicators, installed technology trends, policy environments, workflow requirements, equipment replacement patterns, and regional infrastructure conditions. The methodology should exclude unsupported assumptions and avoid reliance on unverified claims, with emphasis on data validation, source credibility, and consistency across geographies and end-use settings.

Conclusion: Nuclear Imaging Equipment as a Driver of Precision Care

Nuclear imaging equipment is positioned at the intersection of molecular diagnostics, personalized medicine, and digitally enabled healthcare delivery. The field is being reshaped by hybrid imaging, AI-supported workflows, theranostic applications, radiotracer innovation, and the need for efficient, lower-dose, high-confidence diagnostic pathways. Regional adoption remains uneven, with mature systems focused on modernization and workflow optimization, while emerging healthcare systems prioritize access expansion, infrastructure development, and specialist training. Industry success will depend on delivering clinically validated technology, reliable service ecosystems, interoperable software, and adaptable commercial models. As healthcare providers seek earlier detection, more accurate staging, therapy selection, and better treatment monitoring, nuclear imaging equipment will remain essential to advanced diagnostic and therapeutic decision-making.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Nuclear Imaging Equipment Market, by Product Type

• 7.1. Introduction
• 7.2. Single Photon Emission Computed Tomography
• 7.3. Positron Emission Tomography
• 7.4. Planar Scintigraphy Systems
• 7.5. Nuclear Imaging Software & Workstations
• 7.6. Accessories & Ancillary Equipment

8. Nuclear Imaging Equipment Market, by Modality

• 8.1. Introduction
• 8.2. Diagnostic Nuclear Imaging
• 8.3. Therapeutic Nuclear Imaging

9. Nuclear Imaging Equipment Market, by Technology

• 9.1. Introduction
• 9.2. Analog Nuclear Imaging Systems
• 9.3. Digital Nuclear Imaging Systems
• 9.4. Hybrid Imaging Technology

10. Nuclear Imaging Equipment Market, by Detector Type

• 10.1. Introduction
• 10.2. Scintillation Detectors
• 10.3. Semiconductor Detectors

11. Nuclear Imaging Equipment Market, by Application

• 11.1. Introduction
• 11.2. Cardiology
• 11.3. Infectious Disease Diagnosis
• 11.4. Neurology
• 11.5. Oncology
• 11.6. Orthopedics

12. Nuclear Imaging Equipment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Nuclear Imaging Equipment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Nuclear Imaging Equipment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Absolute Imaging Inc.
• 16.2. Advanced Accelerator Applications S.A. by Norvatis
• 16.3. Agfa-Gevaert N.V
• 16.4. Bayer AG
• 16.5. Bozlu Holding A. S.
• 16.6. Bracco Imaging S.p.A.
• 16.7. Canon Medical Systems Corporation
• 16.8. CMR Naviscan Corporation
• 16.9. Cubresa Inc.
• 16.10. DDD-Diagnostic A/S
• 16.11. Digirad Corporation
• 16.12. Edge Medical Solutions Private Limited
• 16.13. GE HealthCare Technologies Inc.
• 16.14. Koninklijke Philips N.V.
• 16.15. Mediso Ltd.
• 16.16. MR Solutions Ltd.
• 16.17. Neusoft Medical Systems Co., Ltd.
• 16.18. PerkinElmer Inc.
• 16.19. Revvity Inc
• 16.20. Rigaku Corporation
• 16.21. Shimadzu Corporation
• 16.22. Siemens AG
• 16.23. Surgiceye GmbH
• 16.24. United Imaging Healthcare Co., Ltd.